ClinicalTrials.gg
TerminatedNCT00836875Updated Jun 16, 2017Results posted

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

A Phase 3 interventional study of Voriconazole in Invasive Aspergillosis, sponsored by Pfizer. Terminated at 25 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.

Enrollment
7th of 17
31 · median 24
Started
2009
the only one that year
Phase 3
5 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
6 of 17
Pfizer

Among the 17 studies testing voriconazole in Aspergillosis, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 9th registered.

Aspergillosis

134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.

Browse Aspergillosis studies →

Open to participants now

None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Aspergillosis as a file.
02

Study summary

The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.

03

Conditions studied

  • Invasive Aspergillosis

Browse trials for

Keywords

  • Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with clinically compatible illness.
  • Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions).
  • Diagnosis of infection due to Scedosporium or Fusarium species.
  • Male and female from 2 to 17 years of age.
  • Females with must have negative pregnancy test and be using appropriate .

Exclusion criteria

Exclusion Criteria:

  • Allergy or to the azole drugs.
  • Female subjects who are pregnant or lactating.
  • Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection.
  • Received within 24 hours prior to enrollment drugs that may cause prolongation.
  • Significant liver, kidney or heart dysfunction.
  • Not expected to survive for at least 5 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    1

    Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).

    Drug: Voriconazole

Interventions

  • All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy. Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator. Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Baseline, daily while hospitalized, Days 7, 14, 28, 42, 84, and 114, at end of treatment, and up to 1 month post treatment

Secondary outcomes

  1. Percentage of Participants With a Global Response of Success

    Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to \<90% resolution of the radiological lesions attributed to IA at Baseline.

    Time frame: Weeks 6 and End of Treatment (EOT; up to Week 12)

  2. All-Cause Mortality - Number of Participant Deaths

    Number of participant deaths reported at Week 6 and at EOT (up to Week 12).

    Time frame: Week 6 and EOT (up to Week 12)

  3. Attributable Mortality - Number of Participant Deaths

    Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12).

    Time frame: Weeks 6 and EOT (up to Week 12)

  4. Time to Death

    Time frame: Baseline up to 1 month post treatment

07

Results

Posted Jun 23, 2014
Limitations and caveats
The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.

Participant flow

Participant flow — Overall Study
MilestoneVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Started1120
Completed817
Not completed33
Withdrew: Death32
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)
Time frame:
Baseline, daily while hospitalized, Days 7, 14, 28, 42, 84, and 114, at end of treatment, and up to 1 month post treatment
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
With AEs1119
With serious AEs69
With severe AEs58
Discontinued treatment due to AEs10
Dose reduced or temporarily discontinued due to AE04
SecondaryPercentage of Participants With a Global Response of Success

Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to \<90% resolution of the radiological lesions attributed to IA at Baseline.

Time frame:
Weeks 6 and End of Treatment (EOT; up to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants With a Global Response of Success
percentage of participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Week 640.0 (5.3 to 85.3)77.8 (40.0 to 97.2)
EOT40.0 (5.3 to 85.3)77.8 (40.0 to 97.2)
SecondaryAll-Cause Mortality - Number of Participant Deaths

Number of participant deaths reported at Week 6 and at EOT (up to Week 12).

Time frame:
Week 6 and EOT (up to Week 12)
Reported as:
Number · participants
All-Cause Mortality - Number of Participant Deaths
participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Week 631
EOT01
SecondaryAttributable Mortality - Number of Participant Deaths

Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12).

Time frame:
Weeks 6 and EOT (up to Week 12)
Reported as:
Number · participants
Attributable Mortality - Number of Participant Deaths
participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Attributable Mortality - Number of Participant Deaths00
SecondaryTime to Death
Time frame:
Baseline up to 1 month post treatment
Reported as:
Median · days
Time to Death
daysVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Time to Death30.0 (18 to 38)47.5 (20 to 75)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole: 2 to <12 Years—6/11 (54.5%)10/11 (90.9%)
Voriconazole: 12 to <18 Years—9/20 (45%)19/20 (95%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Septic shockInfections and infestations2/112/20
Febrile neutropeniaBlood and lymphatic system disorders1/112/20
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/112/20
NeutropeniaBlood and lymphatic system disorders1/110/20
Cardiac arrestCardiac disorders1/110/20
Lower gastrointestinal haemorrhageGastrointestinal disorders1/110/20
AspergillosisInfections and infestations1/110/20
SepsisInfections and infestations1/111/20
HypoglycaemiaMetabolism and nutrition disorders1/110/20
HypokalaemiaMetabolism and nutrition disorders1/110/20
Most frequent other events
Showing 10 of 164
Most frequent other events
EventVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
PyrexiaGeneral disorders0/117/20
DiarrhoeaGastrointestinal disorders3/111/20
Upper respiratory tract infectionInfections and infestations3/111/20
HypocalcaemiaMetabolism and nutrition disorders3/110/20
HypophosphataemiaMetabolism and nutrition disorders3/110/20
EpistaxisRespiratory, thoracic and mediastinal disorders2/114/20
Procedural painInjury, poisoning and procedural complications2/112/20
HypomagnesaemiaMetabolism and nutrition disorders2/111/20
HyponatraemiaMetabolism and nutrition disorders2/110/20
CoughRespiratory, thoracic and mediastinal disorders2/112/20

Baseline characteristics

Safety population: included all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Voriconazole: 2 to <12 YearsVoriconazole: 12 to <18 YearsTotal
Mean7.9 ± 2.314.1 ± 1.711.9 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)Voriconazole: 2 to <12 YearsVoriconazole: 12 to <18 YearsTotal
Female41115
Male7916
08

Study locations

25 sites
  • Childrens Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital & Research Center Oakland (CHRCO)
    Oakland, California 94609, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Children's Pavilion, Virginia Commonwealth University Health System
    Richmond, Virginia 23219, United States
  • Virginia Commonwealth University Health System, Hospital Pharmacy
    Richmond, Virginia 23298-0042, United States
  • Pediatric Hematology and Oncology, Virginia Commonwealth University Health System
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University/MCV Clinical Pathology
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Alberta Children's Hospital, Pediatric Oncology Office
    Calgary, Alberta T3B 6A8, Canada
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Brno
    Brno, 62500, Czechia
  • UMC St. Radboud
    Nijmegen, 6500 HB, Netherlands
  • Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej
    Wroclaw, 50-345, Poland
  • National University Hospital
    Singapore, 119074, Singapore
  • KK Women's and Children's Hospital
    Singapore, 229899, Singapore
  • Hospital General Universitari Vall D'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitari Vall d'Hebron. Servicio de Farmacia
    Barcelona, 08035, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • HOSPITAL UNIVERSITARIO 12 DE OCTUBRE Servicio de Farmacia
    Madrid, 28041, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University
    Bangkok noi, Bangkok 10700, Thailand
  • Department of Pediatrics, Faculty of Medicine, Chulalongkorn University
    Patumwan, Bangkok 10330, Thailand
  • Department of Pediatrics, Phramongkutklao hospital
    Rajathevee, Bangkok 10400, Thailand
09

References and documents

Publications

  • Martin JM, Macias-Parra M, Mudry P, Conte U, Yan JL, Liu P, Capparella MR, Aram JA. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatr Infect Dis J. 2017 Jan;36(1):e1-e13. doi: 10.1097/INF.0000000000001339. PubMed 27636722 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2009 to primary completion in May 2013, 48 months.

Results were first posted in Jun 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2009
First posted
Feb 4, 2009
StartActual
May 2009
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jun 23, 2014
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00836875
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 4, 2009
Start date
May 2009
Primary completion
May 2013
Completion
May 2013
Results posted
Jun 23, 2014
Last update
Jun 16, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion